Keywords: fda, fast-tracks, cure, data, review, plavix, food
FDA fast-tracks CURE data review for Plavix
Article | 10 September 2001
The US Food and Drug Administration has decided to grant a priorityreview to Bristol-Myers Squibb and Sanofi-Synthelabo's Plavix (clopidogrel) as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
